Revolution Medicines, Inc.

This study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check safety and find the right dose. This is an early-phase trial, so it foc…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in 420 adults with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated. The goal is to see if the new drug can delay cancer growth and extend life. …

This study tests a combination of experimental drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink or control tumors. About 370 participants whose cancer has worsen…

This study tests a new drug called daraxonrasib to see if it can delay or prevent pancreatic cancer from returning after surgery and chemotherapy. About 500 adults who have had their pancreatic cancer removed will be randomly assigned to receive the drug or just be watched. The g…

This study tests a new drug called daraxonrasib, which targets a common cancer-driving protein (RAS). It is given alone or with standard chemotherapy to people with metastatic pancreatic cancer that has spread. The goal is to see if the new drug helps people live longer or slows …

This study tests two experimental drugs, elironrasib and daraxonrasib, alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if these drugs are safe and can shrink or control tumors. About 534 adults with lung, colorec…

This program provides the experimental drug daraxonrasib to adults with advanced pancreatic cancer that has spread and worsened after prior treatments. It is for patients who have no good standard options and cannot join a daraxonrasib clinical trial. The goal is to offer a poten…

This study tests new drugs called RAS(ON) inhibitors in people with a type of lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors. About 616 adults with advanced lung cancer will receive the drugs alone or with standard treatments…

This study is testing several new experimental drugs called RAS(ON) inhibitors, alone or with standard chemotherapy, in people with advanced colorectal or pancreatic cancer that has spread. About 1,130 adults will participate to see if these combinations are safe and can shrink t…

This study tests a new drug called RMC-5127 in people with advanced solid tumors that have a specific KRAS G12V gene change. The drug is given alone or with other medicines to see if it is safe and can shrink tumors. About 574 adults who have already tried other treatments will t…